SCHEMBL15428601

SCHEMBL15428601

Cc1cc(C(N)=O)n(-c2cc(Cl)ccc2Cl)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.52
L3MBTL1 Q9Y468 4/20 0.49
KDM4E B2RXH2 1/20 0.49
JAK2 O60674 3/20 0.43
JAK1 P23458 2/20 0.43
TYK2 P29597 1/20 0.43
JAK3 P52333 1/20 0.43
MAPT P10636 1/20 0.42
NOTUM Q6P988 1/20 0.42
ALDH1A1 P00352 3/20 0.41
OPRM1 P35372 1/20 0.41
F10 P00742 1/20 0.41
LMNA P02545 2/20 0.40
NTRK1 P04629 1/20 0.40
MEN1 O00255 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
KMT2A Q03164 1/20 0.40
HSD17B10 Q99714 1/20 0.40
THRB P10828 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15428755 0.89 L3MBTL1 (0.41) HTTL3MBTL1KDM4EJAK2JAK1
SCHEMBL15428770 0.84 PDE4B (0.44) L3MBTL1KDM4EMAPTNOTUMALDH1A1
SCHEMBL15428694 0.83 KDM4E (0.40) HTTL3MBTL1KDM4EJAK2JAK1
SCHEMBL15428640 0.83 JAK2 (0.48) L3MBTL1JAK2JAK1TYK2MAPT
SCHEMBL15428721 0.81 POLB (0.53) HTTL3MBTL1KDM4EMAPTALDH1A1
SCHEMBL11334891 0.77 CYP1A2 (0.49) HTTL3MBTL1KDM4EJAK2JAK1
SCHEMBL5807693 0.77 HTT (0.51) HTTL3MBTL1KDM4EJAK2JAK1
SCHEMBL28171784 0.77 KDM4E (0.51) HTTL3MBTL1KDM4EMAPTALDH1A1
SCHEMBL15428647 0.77 L3MBTL1 (0.44) L3MBTL1KDM4EMAPTNOTUMALDH1A1
SCHEMBL15428570 0.77 HTT (0.45) HTTL3MBTL1KDM4EJAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160244456-A1 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS GENENTECH, INC. (US) 2016-08-25 US disclosed
EP-2348860-B1 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS GENENTECH INC (US) 2015-05-27 EP disclosed
US-20140107099-A1 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS GENENTECH, INC. (US) 2014-04-17 US disclosed
US-8637526-B2 Pyrazolopyrimidine JAK inhibitor compounds and methods GENENTECH, INC. (US) 2014-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140107099-A1 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS JAK2, JAK1, JAK3 HTT 4391/4885L3MBTL1 1966/4885KDM4E 1299/4885
US-20160244456-A1 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS JAK2, JAK1, JAK3 HTT 4391/4885L3MBTL1 1966/4885KDM4E 1299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.